"Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure

The ASTRONAUT Randomized Trial"

JAMA Mar 20 (online first)
http://jama.jamanetwork.com/article.aspx?articleid=1666394
"Conclusion and Relevance  Among patients hospitalized for HF with reduced LVEF, initiation of aliskiren in addition to standard therapy did not reduce CV death or HF rehospitalization at 6 months or 12 months after discharge."